Co-administration of dolutegravir-based treatment and short course of rifapentine/isoniazid (3HP) well tolerated in people living with HIV
Sixfold increased risk of infant HIV infection and high rates of low birth weight among women with HIV/hepatitis B co-infection
EACS takes steps towards a common, auditable European standard of care
HIV capsid inhibitor may offer long-term viral suppression
One in six South Africans drug resistant before starting HIV treatment
People stay on PrEP for 14 months on average in the US, study finds
Are CD4 counts still useful in the 'treat all' era?
Multiple benefits to scaling up universal test and treat in Africa
Long-acting injectable treatment maintains viral suppression
